|Generic name||Loncastuximab tesirine-lpyl|
|Brand name(s), other common name(s)||Zynlonta™|
|Drug type||CD19-directed antibody and alkylating agent conjugate|
|How the drug is given||Intravenously (IV)|
Indications and Usage
Loncastuximab tesirine-lpyl is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Side effects needing medical attention
Most common adverse reactions, including laboratory abnormalities, are thrombocytopenia (low platelet level), increased gamma-glutamyltransferase (enzyme that is found in many organs throughout the body, with the highest concentrations found in the liver), neutropenia (low count of neutrophils, a type of white blood cell), anemia (blood doesn't have enough healthy red blood cells), hyperglycemia (high blood sugar levels), transaminase elevation (liver enzymes), fatigue, hypoalbuminemia (level of albumin in the blood is low), rash, edema (swelling caused by excess fluid trapped in the body's tissues), nausea, and musculoskeletal pain (pain in muscles, bones, ligaments, tendons, and nerves).